Patents by Inventor Yajun BAI

Yajun BAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230216064
    Abstract: A method for producing a membrane electrode comprises a thermal transfer printing step, a thermal combining step, a carbon paper attaching step and a hot-pressing step. The invention realizes the continuous automatic production of the membrane electrode and improves the production efficiency and the quality of the membrane electrode.
    Type: Application
    Filed: September 9, 2022
    Publication date: July 6, 2023
    Inventors: Guanghui SONG, Zhongqiang LIU, Yajun BAI, Guangpeng SHI, Tao CUI, Dalong WANG, Chengguang WANG
  • Patent number: 11371065
    Abstract: The present disclosure discloses a genetically engineered strain, belonging to the technical field of bioengineering. L-amino acid oxidase genes, ?-keto acid decarboxylase genes, alcohol dehydrogenase genes, and enzyme genes capable of reducing NAD(P) to NAD(P)H are introduced into the genetically engineered strain of the present disclosure. The present disclosure further discloses a construction method and application of a recombinant Escherichia coli genetically engineered strain. When being applied to the biosynthesis of phenylethanoids, the method of the present disclosure has the characteristics of simple operation, low cost, and high synthesis efficiency and optical purity of the product, and has good industrialization prospects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 28, 2022
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Yujie Cai, Jinbin Liu, Tianzhen Xiong, Yanrui Ding, Yajun Bai, Xiaohui Zheng
  • Patent number: 11358985
    Abstract: Provided are a tripeptide compound, a preparation method therefor, and an application thereof. The structure of the related compound is represented by formula (I). The provided compound has angiotensin converting enzyme inhibiting bioactivity, and the compound and a pharmaceutical composition thereof play a role in preventing and treating hypertension and other cardiocerebral vascular system diseases.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: June 14, 2022
    Assignee: NORTHWEST UNIVERSITY
    Inventors: Xiaohui Zheng, Yajun Bai, Fanggang Qin, Pei Liu, Jiacheng Fang, Xirui He, Xiaoxiao Wang
  • Publication number: 20210207105
    Abstract: The disclosure discloses a strain and method for producing rosmarinic acid, and belongs to the technical field of bioengineering. The disclosure constructs a recombinant cell or a combination of recombinant cells expressing 4-coumarate: CoA ligase, rosmarinic acid synthase, polyphosphate kinase 2-I (PPK2-I) and polyphosphate kinase 2-II (PPK2-II), and utilizes the recombinant cell or the combination of recombinant cells to catalyze Danshensu and caffeic acid for synthesizing rosmarinic acid. The disclosure has good industrial application prospects.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 8, 2021
    Inventors: Yujie CAI, Yi YAN, Yanrui DING, Yajun BAI, Xiaohui ZHENG
  • Patent number: 10993926
    Abstract: Use of isopropyl ?-(3,4-dihydroxyphenyl)-?-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggregation, to promote angiogenesis, and to prepare a drug and a health product for prevention and treatment of senile vascular dementia.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 4, 2021
    Assignee: NORTHWEST UNIVERSITY
    Inventors: Xiaohui Zheng, Yajun Bai, Pu Jia, Yajun Zhang, Sha Liao
  • Patent number: 10870870
    Abstract: The present disclosure discloses an engineering strain and application thereof in joint production of Danshensu and alanine, and belongs to the technical field of bioengineering. The present disclosure constructs a three-enzyme co-expression genetic engineering strain, and realizes joint production of Danshensu and alanine. Further, the transport of a substrate is promoted and decomposition of products is reduced by knocking out or enhancing expression of related genes on E. coli genome. The genetic engineering strain provided by the present disclosure can produce optically pure D-danshensu and L-danshensu, and jointly produce pyruvic acid. The production process is simple, raw materials are easily available, impurities are fewer, and a good industrial application prospect is achieved.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: December 22, 2020
    Assignee: Jiangnan University
    Inventors: Yujie Cai, Tianzhen Xiong, Jinbin Liu, Yanrui Ding, Yajun Bai, Xiaohui Zheng
  • Patent number: 10829790
    Abstract: The present disclosure discloses a production method of Danshensu, belonging to the technical field of bioengineering. The present disclosure constructs a novel genetic engineering strain co-expressed by three enzymes, which can be applied to the production of optically pure 3-(3,4-dihydroxyphenyl)-2-hydroxypropionic acid. All of the (D/L)-?-hydroxycarboxylic acid dehydrogenase selected by the present disclosure have the characteristics of poor substrate specificity and strong optical specificity, and can produce optically pure D-danshensu and L-danshensu. Further, the production efficiency of the recombinant strain is improved by knocking out or enhancing the expression of a related gene on the E. coli genome to promote substrate transport and reduce product decomposition.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 10, 2020
    Assignee: Jiangnan University
    Inventors: Yujie Cai, Tianzhen Xiong, Jinbin Liu, Yanrui Ding, Yajun Bai, Xiaohui Zheng
  • Publication number: 20200038357
    Abstract: Use of isopropyl ?-(3,4-dihydroxyphenyl)-?-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggregation, to promote angiogenesis, and to prepare a drug and a health product for prevention and treatment of senile vascular dementia.
    Type: Application
    Filed: September 29, 2017
    Publication date: February 6, 2020
    Inventors: Xiaohui ZHENG, Yajun BAI, Pu JIA, Yajun ZHANG, Sha LIAO
  • Publication number: 20190376100
    Abstract: The present disclosure discloses an engineering strain and application thereof in joint production of Danshensu and alanine, and belongs to the technical field of bioengineering. The present disclosure constructs a three-enzyme co-expression genetic engineering strain, and realizes joint production of Danshensu and alanine. Further, the transport of a substrate is promoted and decomposition of products is reduced by knocking out or enhancing expression of related genes on E. coli genome. The genetic engineering strain provided by the present disclosure can produce optically pure D-danshensu and L-danshensu, and jointly produce pyruvic acid. The production process is simple, raw materials are easily available, impurities are fewer, and a good industrial application prospect is achieved.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 12, 2019
    Inventors: Yujie CAI, Tianzhen XIONG, Jinbin LIU, Yanrui DING, Yajun BAI, Xiaohui ZHENG
  • Publication number: 20190360007
    Abstract: The present disclosure discloses a production method of Danshensu, belonging to the technical field of bioengineering. The present disclosure constructs a novel genetic engineering strain co-expressed by three enzymes, which can be applied to the production of optically pure 3-(3,4-dihydroxyphenyl)-2-hydroxypropionic acid. All of the (D/L)-?-hydroxycarboxylic acid dehydrogenase selected by the present disclosure have the characteristics of poor substrate specificity and strong optical specificity, and can produce optically pure D-danshensu and L-danshensu. Further, the production efficiency of the recombinant strain is improved by knocking out or enhancing the expression of a related gene on the E. coli genome to promote substrate transport and reduce product decomposition.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Yujie CAI, Tianzhen XIONG, Jinbin LIU, Yanrui DING, Yajun BAI, Xiaohui ZHENG
  • Publication number: 20190136269
    Abstract: The present disclosure discloses a genetically engineered strain, belonging to the technical field of bioengineering. L-amino acid oxidase genes, ?-keto acid decarboxylase genes, alcohol dehydrogenase genes, and enzyme genes capable of reducing NAD(P) to NAD(P)H are introduced into the genetically engineered strain of the present disclosure. The present disclosure further discloses a construction method and application of a recombinant Escherichia coli genetically engineered strain. When being applied to the biosynthesis of phenylethanoids, the method of the present disclosure has the characteristics of simple operation, low cost, and high synthesis efficiency and optical purity of the product, and has good industrialization prospects.
    Type: Application
    Filed: November 30, 2018
    Publication date: May 9, 2019
    Inventors: Yujie CAI, Jinbin LIU, Tianzhen XIONG, Yanrui DING, Yajun BAI, Xiaohui ZHENG
  • Patent number: 10131619
    Abstract: The present invention relates to ?-asary-laldehyde ester. The chemical structure of the related ?-asary-laldehyde ester is of formula I.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: November 20, 2018
    Assignee: NORTHWEST UNIVERSITY
    Inventors: Xiaohui Zheng, Fanggang Qin, Yajun Bai, Shixiang Wang, Yi Zhang, Xirui He, Pei Liu
  • Publication number: 20170267718
    Abstract: Provided are a tripeptide compound, a preparation method therefor, and an application thereof. The structure of the related compound is represented by formula (I). The provided compound has angiotensin converting enzyme inhibiting bioactivity, and the compound and a pharmaceutical composition thereof play a role in preventing and treating hypertension and other cardiocerebral vascular system diseases.
    Type: Application
    Filed: November 27, 2015
    Publication date: September 21, 2017
    Inventors: Xiaohui ZHENG, Yajun BAI, Fanggang QIN, Pei LIU, Jiacheng FANG, Xirui HE, Xiaoxiao WANG
  • Publication number: 20170260122
    Abstract: The present invention relates to ?-asary-laldehyde ester, a preparation method therefor, and an application thereof. The chemical structure of the related ?-asary-laldehyde ester is represented by formula I. A related application is an application of the compound in preparation of drugs for calming, mind tranquillizing, senile dementia resisting, convulsion resisting, epilepsy resisting and depression resisting.
    Type: Application
    Filed: November 26, 2015
    Publication date: September 14, 2017
    Applicant: NORTHWEST UNIVERSITY
    Inventors: Xiaohui ZHENG, Fanggang QIN, Yajun BAI, Shixiang WANG, Yi ZHANG, Xirui HE, Pei LIU